Fidson Invests ₦3.7bn To Boost Local Pharma Production In 2024

Fidson Healthcare Plc, Nigeria’s pharmaceutical manufacturer, has reinforced its leadership in 2024 with a ₦3.7 billion investment in local pharmaceutical manufacturing infrastructure, an aggressive move that underlines its commitment to homegrown healthcare solutions.

The investment, aimed at expanding production capacity and reducing reliance on imported medicines, comes as the company reported a record ₦84.2 billion in revenue, representing a 59 per cent year-on-year increase from ₦53.1 billion in 2023.

This development is central to Fidson’s long-term strategy, which is to scale local pharmaceutical production to meet rising national demand, while ensuring cost efficiency, accessibility, and supply chain resilience in an industry critical to Nigeria’s health system.

The Nigerian company, which hit the 30-year milestone in 2025, has demonstrated a strong growth trajectory over the years, making it an attractive prospect for investors. Today, it is the largest pharmaceutical company in Nigeria with a market capitalization of approximately 44.64 billion naira as of April 2025. According to the 2024 audited financial statements, Fidson recorded a 59 per cent increase in revenue, growing from ₦53.1 billion in 2023 to ₦84.2 billion. While profits before tax rose to ₦7.7 billion, representing a 30 per cent growth, the net profit surged by an impressive 60 per cent to ₦5.78 billion.

The finance director, Fidson Healthcare Plc, Mr. Imokha Ayebae, while speaking to newsmen, explained that these achievements were not accidental.

“They were the result of operational efficiency, prudent financial management, and a good relationship with critical stakeholders in the Nigerian market,” he stated.

Also, earnings per share climbed from 157 kobo to 252 kobo, and net asset per share rose by 23 percent to 1,034 kobo—signaling strong shareholder value creation. In a bold expression of confidence in its future cash flow and profitability, the company proposes an increase in its dividend payout from ₦0.60 to ₦1.00 per share, amounting to ₦2.29 billion in total. This remarkable financial success rides on Fidson’s clinical adherence to global standards in every facet of the organization’s processes. At the core of its business is the world-class WHO-complaint manufacturing facility in Ogun State.

The deputy managing director, Mr. Biola Adebayo, revealed that the company invests heavily in its manufacturing capabilities, adding that, “Since embarking on local production in 2002, the company has maintained a steady growth trajectory, consistently expanding its production capabilities in line with the current Global Manufacturing Practices (cGMP).”

In 2024 alone, Fidson reinforced this edge by investing over ₦3.7 billion in property, plant, and equipment, signifying not just a commitment to meeting growing demand but also a strategic focus on reducing dependence on imported drugs. The company’s ability to produce high-quality pharmaceutical products locally—from tablets to infusions and injectables is unrivaled. Today, Fidson is the leading LVP manufacturer in Africa, producing over 120 million bottles annually. The company is also the manufacturer of glass-ampoule injectables in Nigeria. This has played a pivotal role in enhancing national health security while simultaneously fostering affordability and accessibility across the country.

Complementing these manufacturing capabilities is a robust logistics and distribution system. The company has cultivated a vast and reliable network that spans all geopolitical zones in Nigeria, ensuring the seamless movement of products from factory floors to hospital shelves and retail pharmacies. With 11 purpose-built depots operated across Nigeria’s geopolitical regions already, more depots are in the works to ensure efficient distribution of life-saving medicines to reinforce the brand’s reputation for reliability in a market where timely access to medicines is critical.

Yet, Fidson’s most valuable asset remains its people. With a workforce of over 1,709 employees, the company has cultivated a culture rooted in professionalism, inclusivity, and continuous learning. It maintains a policy of non-discrimination, offering equal opportunities to all. Beyond statutory obligations, the company goes further to prioritize employee well-being by offering comprehensive health insurance for all staff, performance-based incentives and even free meals for low-income workers. Its approach to talent development—through training, upskilling, and leadership grooming—has created a resilient and motivated team capable of navigating the dynamic terrain of pharmaceutical manufacturing, marketing and distribution.

In 2025, Fidson Healthcare strives to expand its leadership. With continued investments in infrastructure and expertise, actively exploring new markets across Africa, and strategic partnerships across the healthcare value chain, the company is poised to deepen its market penetration and broaden its impact on public health outcomes in Africa. Its CSR expenditure (amounting to ₦248 million in 2024) demonstrates a deep sense of social responsibility, further strengthening its community ties, corporate legacy and environmental sustainability.